Verastem, Inc.
Every calculator, already run for VSTM
Open the full toolkit →You have the numbers on VSTM. Get the argument.
A written report on which of these readings actually decide the outcome for Verastem, Inc., what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
10 analysts covering VSTMAnalyst Price Target Disagreement for Verastem, Inc.
Wall Street's bull case implies +134% from the current price; the bear case implies +43%. A 91% spread signals high analyst disagreement — run your own DCF to anchor on fundamentals rather than street consensus.
Ownership & short interest
Insider Trading Activity for VSTM
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About Verastem, Inc.
Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, which is an orally administered, small molecule dual RAF/MEK inhibitor developed to block MEK kinase activity and the compensatory reactivation of MEK by upstream RAF, thereby targeting the RAS/MAPK signaling pathway that is commonly activated in various cancers; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the…
VSTM — frequently asked
Is VSTM a buy right now?
Wall Street's consensus rating on Verastem, Inc. is Strong Buy across 10 analysts, with a mean price target of $14.67 (+90% vs. the current $7.70). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
When is VSTM's next earnings date?
Verastem, Inc. is next scheduled to report earnings around Nov 3, 2026. A full VSTM research report from Basis Report covers the setup into that print — estimates, the beat/miss record, and what would move the thesis.
What is the analyst price target disagreement for Verastem, Inc.?
Analysts covering Verastem, Inc. (VSTM) range from a bear-case target of $11.00 to a bull-case high of $18.00, with a mean consensus target of $14.67 across 9 analysts. The spread of $7.00 (91% of the current price) indicates high disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare Verastem, Inc. against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Verastem, Inc.
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full VSTM research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Verastem, Inc., in minutes. 3 free reports included with every account — no credit card required.